The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- VALUING AND ACCESSING MEDICINES
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- HEALTH DATA
VALUING AND ACCESSING MEDICINES
Value and Access
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
RESEARCH, DEVELOPMENT AND MANUFACTURING
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
WORKING IN PARTNERSHIP
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
INDUSTRY REPUTATION
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
INTERNATIONAL, TRADE AND IP
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
HEALTH DATA
Health data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
Partnering with purpose: How integrated care systems and industry can work better together
The NHS Confederation and the ABPI have published a joint report on how Integrated Care Systems (ICSs) and industry can work better together in the interests of patients.
NHS Industry Case Studies Library
Partnerships between the NHS and the pharmaceutical industry benefit patients and the NHS. Visit the ABPI's library of case studies of successful partnerships.
Getting back on track: Restoring the UK’s global position in industry clinical trials
To achieve its science and technology superpower ambitions and improve the health and wealth of the nation, the government must restore the UK’s global position in industry clinical trials and maximise their benefits to patients, the NHS, and the UK economy.
M5 Advanced Manufacturing: Powering the UK Economy
New report sets out the reforms necessary for the UK to close the gap with global competitors and unlock the potential for manufacturing to drive prosperity and pride across the UK.
Latest news
Government sends mixed message to global life science investors
The government has published new terms for the Statutory Scheme for branded medicines, maintaining sales rebates at levels which have damaged the UK’s international standing with global life science companies.
ABPI response to UK Biobank whole genome sequencing dataset
The UK Biobank has revealed a new data from whole genome sequencing from half a million participants.
Break down barriers to partnerships to change the lives of millions, say NHS Confederation and the ABPI
Partnerships between the NHS and the pharmaceutical industry can change the lives of millions of people across the country, according to a new report.
ABPI comment on Government's full response to the O'Shaughnessy Review
The ABPI has commented on the Government's full response to the O'Shaughnessy Review.
Latest blogs and events
What the pandemic taught us about international trade rules for health - and how we can make them better for the future
Blog post by Ben Lucas, Managing Director, MSD UK & Ireland and ABPI Board Sponsor, International and Intellectual Property Policy
Paving the way to sustainability: transforming pharmaceutical industry practices
Blog post by Roz Bekker, Managing Director Janssen UK & Ireland, ABPI Sustainability Board Sponsor
British Neuroscience Association Scholars Day
The pharmaceutical industry is a vast and dynamic sector. It offers countless career opportunities for scientists, as well as other important non-science roles, and welcomes people from diverse backgrounds and career stages.
Online Workshop on SMC: How to prepare and submit to SMC | 11-12 March 2024
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
Key content hubs
The COP28 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/b10ppsss/40-8bn-turnover.jpg)
![R and D Investment [2]](/media/ouqnhlry/figures-r-d-investment-5-0bn.jpg)
![Gross Value Added (GVA) [4]](/media/fi4hkeqh/figures-gva-14bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.